RECRUITING

Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study evaluates individuals without pancreatic cancer, but who have been determined to be at higher-than-average lifetime risk of developing pancreatic cancer to help detect pancreatic cancer or other cancers at an earlier time when they might be more easily treated and cured.

Official Title

Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts

Quick Facts

Study Start:2024-12-12

Study Completion:2029-11-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06271291

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* PDAC FAMILY HISTORY OR PDAC RELATED GENETIC MUTATIONS: * Age: 50 or older, plus at least one of the following: * Mutation unknown or absent: * 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; * OR 2+ affected first degree relatives (FDR), defined as blood related parents, siblings, or children) * Known pathogenic/likely pathogenic (P/LP) mutation in at least one of the following: * CDKN2A/p16, PJS (STK11), Hereditary pancreatitis with confirmed protease serine 1 (PRSS1) * OR 1+FDR or second degree relative (SDR) with PDAC and a known P/LP mutation in one or more of: * ATM, BRCA1, BRCA2, PALB2, Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM), TP53 * 18 years of age or greater and meeting Fukuoka worrisome (FW) or Fukuoka high-risk (FHR) criteria * High risk stigmata: * Obstructive Jaundice in a patient with cystic lesion of the head of the pancreas * Enhancing mural nodule ≥ 5 mm * Main pancreatic duct ≥ 10 mm * Worrisome features: * Presence of pancreatic duct stricture, defined as focal pancreatic duct narrowing with upstream duct =\> 6 mm * Cyst ≥ 3 cm * Enhancing mural nodule \< 5 mm * Thickened/Enhancing cyst wall * Main duct size 5-9 mm * Pancreatitis * Lymphadenopathy * Increased CA 19-9 * Cyst growth rate ≥ 5 mm /2 years	* \* Is unable to provide informed consent * Has received a non-autologous bone marrow transplant or has an active hematologic malignancy (i.e., leukemia or lymphoma) * Current or prior history of PDAC or total pancreatectomy * Is currently a prison inmate * Is not able to speak or read English

Inclusion Criteria

Exclusion Criteria

* PDAC FAMILY HISTORY OR PDAC RELATED GENETIC MUTATIONS:
* Age: 50 or older, plus at least one of the following:
* Mutation unknown or absent:
* 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject;
* OR 2+ affected first degree relatives (FDR), defined as blood related parents, siblings, or children)
* Known pathogenic/likely pathogenic (P/LP) mutation in at least one of the following:
* CDKN2A/p16, PJS (STK11), Hereditary pancreatitis with confirmed protease serine 1 (PRSS1)
* OR 1+FDR or second degree relative (SDR) with PDAC and a known P/LP mutation in one or more of:
* ATM, BRCA1, BRCA2, PALB2, Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM), TP53
* 18 years of age or greater and meeting Fukuoka worrisome (FW) or Fukuoka high-risk (FHR) criteria
* High risk stigmata:
* Obstructive Jaundice in a patient with cystic lesion of the head of the pancreas
* Enhancing mural nodule ≥ 5 mm
* Main pancreatic duct ≥ 10 mm
* Worrisome features:
* Presence of pancreatic duct stricture, defined as focal pancreatic duct narrowing with upstream duct =\> 6 mm
* Cyst ≥ 3 cm
* Enhancing mural nodule \< 5 mm
* Thickened/Enhancing cyst wall
* Main duct size 5-9 mm
* Pancreatitis
* Lymphadenopathy
* Increased CA 19-9
* Cyst growth rate ≥ 5 mm /2 years

* \* Is unable to provide informed consent
* Has received a non-autologous bone marrow transplant or has an active hematologic malignancy (i.e., leukemia or lymphoma)
* Current or prior history of PDAC or total pancreatectomy
* Is currently a prison inmate
* Is not able to speak or read English

Contacts and Locations

Study Contact

Clinical Trials Referral Office

CONTACT

855-776-0015

mayocliniccancerstudies@mayo.edu

Principal Investigator

Ann L. Oberg, PhD

PRINCIPAL_INVESTIGATOR

Mayo Clinic in Rochester

Study Locations (Sites)

Mayo Clinic in Rochester

Rochester, Minnesota, 55905

United States

University of Pittsburgh

Pittsburgh, Pennsylvania, 15232

United States

Collaborators and Investigators

Sponsor: Mayo Clinic

Ann L. Oberg, PhD, PRINCIPAL_INVESTIGATOR, Mayo Clinic in Rochester

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-12-12

Study Completion Date2029-11-01

Study Record Updates

Study Start Date2024-12-12

Study Completion Date2029-11-01

Terms related to this study

Additional Relevant MeSH Terms

Pancreatic Carcinoma